08.17.21
Rank: #10 (Last year: #10)
$477 Million ($1.37 Billion total)
Prior Fiscal: $521.3 Million
Percentage Change: -8.5%
No. of Employees: 3,700
Global Headquarters: Princeton, N.J.
KEY EXECUTIVES:
Peter J. Arduini, President and CEO
Carrie Anderson, Exec. VP and CFO
Glenn G. Coleman, Exec. VP and COO
Robert T. Davis Jr., Exec. VP and President, Tissue Technologies
Michael McBreen, Exec. VP and President, Codman Specialty Surgical
Eric Schwartz, Exec. VP, Chief Legal Officer and Secretary
Kenneth Burhop, Corporate VP, Chief Scientific Officer
Andrea Caruso, Corporate VP, Business Development
Sravan K. Emany, Corporate VP, Commercial Excellenc and Chief Strategy Officer
Steve Leonard, Corporate VP, Global Operations and Supply Chain
Barbara McAleer, Corporate VP, Global Quality
Judith E. O’Grady, R.N., Corporate VP, Global Regulatory Affairs
The tattoo was a bust.
Jalen Richardson wanted a phoenix rising from ashes branded on his right arm, but the ink didn’t take. The black pigment never fully absorbed into his skin, fading instead into scar tissue covering most of the area.
Not one to brood over setbacks, Richardson was unphased by the anomaly. In fact, the unsuccessful marking only strengthened his resolve to emerge from the shadow of his disfigurement.
“My skin is a tattoo in itself,” the Georgia National Guardsman told Emory Medicine magazine this past winter. “My scars tell a story of their own.”
And it’s a remarkable story—one of survival, courage, and perseverance.
Richardson’s tale begins on Sept. 4, 2016, in Atlanta. After finishing work at UPS that afternoon, the motorcycle enthusiast hopped on his 2003 Suzuki GSK and rode with friends around the city’s outskirts. As he headed back downtown, however, an unfamiliar (outside) rider nudged his way into the biker pack, darting behind Richardson, and striking the Suzuki GSK’s back tire.
The bike toppled upon impact; as he hit the asphalt, Richardson’s right hand reflexively squeezed the motorcycle’s throttle, sending “body and bike skidding down the highway in a fiery shower of sparks,” according to Emory Medicine. After coming to rest, Richardson found himself pinned underneath the weight of his bike. As he struggled to free himself, fuel from his leaking gas tank ignited, engulfing both Richardson and the Suzuki in flames.
The explosion, which grazed traffic signs 20 feet above the highway, produced industrial-strength heat that melted Richardson’s bike helmet and instantly fused his nylon-and-mesh riding jacket into the asphalt. Paramedics had to cut Richardson’s jacket off the pavement to free him.
“I’ve worked a lot of motorcycle wrecks out of Lithonia,” DeKalb Fire Rescue first responder Travis Owens recalled to Emory Medicine. “Two bikes on fire with a rider melted to the asphalt? That doesn’t happen every day.”
Neither does the kinds of injuries Richardson sustained in the accident. The fiery crash left the then-20-year-old with third-degree burns on 60-70 percent of his body (trauma suffered by only a fraction of patients admitted to Grady Memorial Hospital Burn Center); his left forearm was practically burned to the bone and would later need to be amputated.
Richardson spent three months in a medically-induced coma as Grady Memorial Hospital doctors rebuilt his charred skin using the Integra Dermal Regeneration Template, a two-layer skin regeneration system. Developed by Princeton, N.J.-based Integra Lifesciences, the Template’s outer layer is made of a thin silicone film that serves as the skin’s epidermis, protecting open wounds from infection and controlling both heat and moisture loss. The inner layer is a mix of pure bovine collagen and glycosaminoglycan (GAG), normal components of human skin. The cross-linked bovine-GAG matrix acts as a scaffold for regenerating a permanent functional dermis. Once the dermal skin is regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
Richardson underwent 14 skin graft surgeries and remained hospitalized for 14 months before being released to rehab. Twenty months after his accident, he rejoined his Georgia National Guard unit (Charlie Company 151, part of the 78th Aviation Troop Command); Richardson has healed so well that he can now outpace his fellow soldiers in a two-mile run. Last fall, he was named the 78th Aviation Troop Command’s Soldier of the Year.
“What I always saw in Jalen was that he was a great person on the inside, no matter how much he wasn’t acting like that on a particular day, or how much things got difficult, I knew that inside—beneath all of that junk—was someone who was worth putting in the time and effort [for],” Emory surgeon Juvanda Hodge recounted in a video on Integra Lifesciences’ website. “We ended up doing an amputation because that [left] arm was burned before it could be salvaged, but after that we were able to put Integra [Dermal Regeneration Template] on the remainder of his amputation stump and grafted it. You have to have a good foundation is what I always say, and Integra gives you that great foundation to start grafting on top of that.”
The Integra Dermal Regeneration Template has been a great foundation not only for burn patients but also for the company itself in the more than 15 years since its introduction. But that foundation was a bit unstable last year as COVID-19 forced hospitals worldwide to postpone or cancel all elective surgeries and non-emergency chronic wound treatments.
Accordingly, Integra’s total revenue took a significant hit in the first half of 2020, falling 17.5 percent to $612.9 million. Sales improved as elective procedures resumed in H2 but nevertheless ended the year at a deficit, slipping 2 percent to $758.8 million. Gains were particularly strong in the Dermal Regeneration Template, nerve, and amniotic tissue product portfolios, according to the company.
Integra’s robust second-half performance, however, failed to fully offset its pandemic-induced losses. Total company revenue fell 9.8 percent to $1.37 billion; Orthopedics and Tissue Technologies sales tumbled 8 percent to $477 million.
“Integra kicked off the year strong and on track against our operating plans when the COVID-19 pandemic quickly disrupted this growth trajectory and adversely impacted our performance,” President and CEO Peter J. Arduini told shareholders in the firm’s 2020 annual report. “We completed strategic investments and operational improvements to bolster our supply and order-fulfillment capabilities at several regenerative product manufacturing facilities. While the impact of the COVID-19 pandemic may be far from over, we are confident the important steps we took in 2020 have set us up for long-term success.”
Perhaps the most important step Integra took to ensure its long-term success was divesting its Extremity Orthopedics Business to Smith+Nephew for $240 million last fall. The business generated roughly $90 million for the company in 2019 and $32.7 million in H1 2020.
The sale covered Integra’s Titan Reverse Shoulder System and various other devices used to repair and reconstruct bones in the ankle, shoulder, hand, wrist, and elbow. The deal complements Smith+Nephew’s existing product portfolio and provides the company admittance into the shoulder replacement and foot/ankle segments.
“Smith+Nephew’s strong focus in orthopedics will enable the business to expand its reach and scale, while allowing the team to thrive in a new environment,” Arduini said in announcing the sale. “This divestiture will increase our focus on Integra’s portfolio of products in neurosurgery, surgical instrumentation, and regenerative medicine, and move us closer to achieving our long-term growth and profitability targets.”
Integra increased its focus rather quickly in regenerative medicine, acquiring Columbia, Md.-based ACell Inc. for up to $400 million in mid-December. ACell develops products for wound management and surgical soft tissue repair—its proprietary porcine urinary bladder matrix platform technology, MatriStem UBM, aims to enhance the body’s ability to restore natural tissue and minimize scarring. It allows for a wide range of characteristics to be incorporated into devices for specific challenges in wound repair, ranging from strong suturable sheet materials designed for abdominal wall surgery to fine granular materials that conform to complex wound surfaces. Products include MicroMatrix, a particulate formulation, as well as Cytal Wound Matrix and Gentrix Surgical Matrix, both sheet formulations for the management of acute and chronic wounds and reinforcement of soft tissue in certain surgical applications.
Integra deemed the ACell deal a “next step” in expanding its Orthopedics and Tissue Technologies segment. The company took similar (albeit smaller) steps earlier last year with the February launch of the AmnioExcel Plus Placental Allograft Membrane, and the U.S. Food and Drug Administration’s (FDA) July clearance of specific neurosurgery indications for CUSA Clarity.
AmnioExcel Plus is a next-generation, thicker, tri-layer, non-side specific allograft consisting of amnion-chorion-amnion layers that helps create an environment for closing complex wounds. The proprietary DryFlex processing technology preserves the inherent growth factors, cytokines and extracellular matrix (ECM) found in native placental tissue.
The CUSA system has been used for decades in neurosurgical applications, but the FDA indication validates CUSA Clarity’s safety and efficacy in resecting tumors with soft to firm consistencies, and removing primary and secondary malignant and benign brain and spinal tumors, including but not limited to meningiomas and gliomas.
The CUSA Clarity Ultrasonic Surgical Aspirator System is an ultrasonically vibrating surgical device which, in combination with irrigation and aspiration, fragments, emulsifies, and removes unwanted tissue. It allows for selective dissection of target tissue like tumors while preserving vessels, ducts, and other delicate structures.
“Integra has a long history of developing technologies that meet surgeons’ needs for enhanced surgical performance, especially for longer and tougher cases, such as brain tumor resections,” Mike McBreen, who was promoted to executive vice president and president of Codman Specialty Surgical last June, said upon the FDA clearance. “This specific indication represents our continued commitment to offering neurosurgeons safe and effective products that help them achieve the best outcomes for their patients.”
$477 Million ($1.37 Billion total)
Prior Fiscal: $521.3 Million
Percentage Change: -8.5%
No. of Employees: 3,700
Global Headquarters: Princeton, N.J.
KEY EXECUTIVES:
Peter J. Arduini, President and CEO
Carrie Anderson, Exec. VP and CFO
Glenn G. Coleman, Exec. VP and COO
Robert T. Davis Jr., Exec. VP and President, Tissue Technologies
Michael McBreen, Exec. VP and President, Codman Specialty Surgical
Eric Schwartz, Exec. VP, Chief Legal Officer and Secretary
Kenneth Burhop, Corporate VP, Chief Scientific Officer
Andrea Caruso, Corporate VP, Business Development
Sravan K. Emany, Corporate VP, Commercial Excellenc and Chief Strategy Officer
Steve Leonard, Corporate VP, Global Operations and Supply Chain
Barbara McAleer, Corporate VP, Global Quality
Judith E. O’Grady, R.N., Corporate VP, Global Regulatory Affairs
The tattoo was a bust.
Jalen Richardson wanted a phoenix rising from ashes branded on his right arm, but the ink didn’t take. The black pigment never fully absorbed into his skin, fading instead into scar tissue covering most of the area.
Not one to brood over setbacks, Richardson was unphased by the anomaly. In fact, the unsuccessful marking only strengthened his resolve to emerge from the shadow of his disfigurement.
“My skin is a tattoo in itself,” the Georgia National Guardsman told Emory Medicine magazine this past winter. “My scars tell a story of their own.”
And it’s a remarkable story—one of survival, courage, and perseverance.
Richardson’s tale begins on Sept. 4, 2016, in Atlanta. After finishing work at UPS that afternoon, the motorcycle enthusiast hopped on his 2003 Suzuki GSK and rode with friends around the city’s outskirts. As he headed back downtown, however, an unfamiliar (outside) rider nudged his way into the biker pack, darting behind Richardson, and striking the Suzuki GSK’s back tire.
The bike toppled upon impact; as he hit the asphalt, Richardson’s right hand reflexively squeezed the motorcycle’s throttle, sending “body and bike skidding down the highway in a fiery shower of sparks,” according to Emory Medicine. After coming to rest, Richardson found himself pinned underneath the weight of his bike. As he struggled to free himself, fuel from his leaking gas tank ignited, engulfing both Richardson and the Suzuki in flames.
The explosion, which grazed traffic signs 20 feet above the highway, produced industrial-strength heat that melted Richardson’s bike helmet and instantly fused his nylon-and-mesh riding jacket into the asphalt. Paramedics had to cut Richardson’s jacket off the pavement to free him.
“I’ve worked a lot of motorcycle wrecks out of Lithonia,” DeKalb Fire Rescue first responder Travis Owens recalled to Emory Medicine. “Two bikes on fire with a rider melted to the asphalt? That doesn’t happen every day.”
Neither does the kinds of injuries Richardson sustained in the accident. The fiery crash left the then-20-year-old with third-degree burns on 60-70 percent of his body (trauma suffered by only a fraction of patients admitted to Grady Memorial Hospital Burn Center); his left forearm was practically burned to the bone and would later need to be amputated.
Richardson spent three months in a medically-induced coma as Grady Memorial Hospital doctors rebuilt his charred skin using the Integra Dermal Regeneration Template, a two-layer skin regeneration system. Developed by Princeton, N.J.-based Integra Lifesciences, the Template’s outer layer is made of a thin silicone film that serves as the skin’s epidermis, protecting open wounds from infection and controlling both heat and moisture loss. The inner layer is a mix of pure bovine collagen and glycosaminoglycan (GAG), normal components of human skin. The cross-linked bovine-GAG matrix acts as a scaffold for regenerating a permanent functional dermis. Once the dermal skin is regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
Richardson underwent 14 skin graft surgeries and remained hospitalized for 14 months before being released to rehab. Twenty months after his accident, he rejoined his Georgia National Guard unit (Charlie Company 151, part of the 78th Aviation Troop Command); Richardson has healed so well that he can now outpace his fellow soldiers in a two-mile run. Last fall, he was named the 78th Aviation Troop Command’s Soldier of the Year.
“What I always saw in Jalen was that he was a great person on the inside, no matter how much he wasn’t acting like that on a particular day, or how much things got difficult, I knew that inside—beneath all of that junk—was someone who was worth putting in the time and effort [for],” Emory surgeon Juvanda Hodge recounted in a video on Integra Lifesciences’ website. “We ended up doing an amputation because that [left] arm was burned before it could be salvaged, but after that we were able to put Integra [Dermal Regeneration Template] on the remainder of his amputation stump and grafted it. You have to have a good foundation is what I always say, and Integra gives you that great foundation to start grafting on top of that.”
The Integra Dermal Regeneration Template has been a great foundation not only for burn patients but also for the company itself in the more than 15 years since its introduction. But that foundation was a bit unstable last year as COVID-19 forced hospitals worldwide to postpone or cancel all elective surgeries and non-emergency chronic wound treatments.
Accordingly, Integra’s total revenue took a significant hit in the first half of 2020, falling 17.5 percent to $612.9 million. Sales improved as elective procedures resumed in H2 but nevertheless ended the year at a deficit, slipping 2 percent to $758.8 million. Gains were particularly strong in the Dermal Regeneration Template, nerve, and amniotic tissue product portfolios, according to the company.
Integra’s robust second-half performance, however, failed to fully offset its pandemic-induced losses. Total company revenue fell 9.8 percent to $1.37 billion; Orthopedics and Tissue Technologies sales tumbled 8 percent to $477 million.
“Integra kicked off the year strong and on track against our operating plans when the COVID-19 pandemic quickly disrupted this growth trajectory and adversely impacted our performance,” President and CEO Peter J. Arduini told shareholders in the firm’s 2020 annual report. “We completed strategic investments and operational improvements to bolster our supply and order-fulfillment capabilities at several regenerative product manufacturing facilities. While the impact of the COVID-19 pandemic may be far from over, we are confident the important steps we took in 2020 have set us up for long-term success.”
Perhaps the most important step Integra took to ensure its long-term success was divesting its Extremity Orthopedics Business to Smith+Nephew for $240 million last fall. The business generated roughly $90 million for the company in 2019 and $32.7 million in H1 2020.
The sale covered Integra’s Titan Reverse Shoulder System and various other devices used to repair and reconstruct bones in the ankle, shoulder, hand, wrist, and elbow. The deal complements Smith+Nephew’s existing product portfolio and provides the company admittance into the shoulder replacement and foot/ankle segments.
“Smith+Nephew’s strong focus in orthopedics will enable the business to expand its reach and scale, while allowing the team to thrive in a new environment,” Arduini said in announcing the sale. “This divestiture will increase our focus on Integra’s portfolio of products in neurosurgery, surgical instrumentation, and regenerative medicine, and move us closer to achieving our long-term growth and profitability targets.”
Integra increased its focus rather quickly in regenerative medicine, acquiring Columbia, Md.-based ACell Inc. for up to $400 million in mid-December. ACell develops products for wound management and surgical soft tissue repair—its proprietary porcine urinary bladder matrix platform technology, MatriStem UBM, aims to enhance the body’s ability to restore natural tissue and minimize scarring. It allows for a wide range of characteristics to be incorporated into devices for specific challenges in wound repair, ranging from strong suturable sheet materials designed for abdominal wall surgery to fine granular materials that conform to complex wound surfaces. Products include MicroMatrix, a particulate formulation, as well as Cytal Wound Matrix and Gentrix Surgical Matrix, both sheet formulations for the management of acute and chronic wounds and reinforcement of soft tissue in certain surgical applications.
Integra deemed the ACell deal a “next step” in expanding its Orthopedics and Tissue Technologies segment. The company took similar (albeit smaller) steps earlier last year with the February launch of the AmnioExcel Plus Placental Allograft Membrane, and the U.S. Food and Drug Administration’s (FDA) July clearance of specific neurosurgery indications for CUSA Clarity.
AmnioExcel Plus is a next-generation, thicker, tri-layer, non-side specific allograft consisting of amnion-chorion-amnion layers that helps create an environment for closing complex wounds. The proprietary DryFlex processing technology preserves the inherent growth factors, cytokines and extracellular matrix (ECM) found in native placental tissue.
The CUSA system has been used for decades in neurosurgical applications, but the FDA indication validates CUSA Clarity’s safety and efficacy in resecting tumors with soft to firm consistencies, and removing primary and secondary malignant and benign brain and spinal tumors, including but not limited to meningiomas and gliomas.
The CUSA Clarity Ultrasonic Surgical Aspirator System is an ultrasonically vibrating surgical device which, in combination with irrigation and aspiration, fragments, emulsifies, and removes unwanted tissue. It allows for selective dissection of target tissue like tumors while preserving vessels, ducts, and other delicate structures.
“Integra has a long history of developing technologies that meet surgeons’ needs for enhanced surgical performance, especially for longer and tougher cases, such as brain tumor resections,” Mike McBreen, who was promoted to executive vice president and president of Codman Specialty Surgical last June, said upon the FDA clearance. “This specific indication represents our continued commitment to offering neurosurgeons safe and effective products that help them achieve the best outcomes for their patients.”